Nabriva Hopes To Relaunch Xenleta In Community Setting As Pandemic Subsides

Moving away from its earlier hospital-based focus with the novel antibiotic, Nabriva also thinks selling Merck & Co.’s Sivextro will provide complementary business.

Antibiotic resistant bacteria closeup biofilm
Nabriva is betting that the market for antibiotics will bounce back in 2021

Nabriva Therapeutics plc. is hardly the first antibiotics company to experience a disappointing product launch, but the COVID-19 pandemic presented multiple unexpected challenges in the months after the August 2019 approval of the first-in-class, semi-synthetic pleuromutilin antibiotic Xenleta. The company’s initial hospital-based focus in community-acquired bacterial pneumonia (CABP) has been scrapped for a community health system focus.

[Sidebar#SC125738]

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Strategy

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.